Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including Galaxy Digital's (GLXY) debut on the Nasdaq, Eli Lilly (LLY) getting a lift ...

Investing.com – Denmark stocks were higher after the close on Monday, as gains in the Consumer Goods, Healthcare and Chemicals... (Reuters) -U.S. President Donald Trump has backed away from a ...

U.S. stocks are set to wrap a winning week as tariff and trade fears ease, President Trump winds down his Middle East trip ...

The move in futures comes after a broadly positive day on Wall Street. The S&P 500 rose 0.72%, while the Nasdaq Composite climbed 1.61% for its fifth straight positive session. The Dow fell 0.64%, ...

executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. Please find below a statement of such trading in shares issued by Novo Nordisk.

Novo Nordisk (NVO) stock in focus as the company promotes FDA-approved Wegovy as a ban for makers of compounding versions ...

Shares of Ozempic and Wegovy manufacturer Novo Nordisk (NYSE: NVO) reacted positively to the news and are up 4.9% as of 10:20 a.m. ET. America has caught Ozempic fever, and 25% of Novo Nordisk's ...

Danish pharmaceutical company Novo Nordisk announced on Friday that chief executive Lars Fruergaard Jørgensen will step down, as the firm's shares dropped around 5% in pre-market trading.

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why NVO stock is a Buy.

Novo Nordisk CEO Lars Fruergaard Jørgensen to step down amid board and market pressure. Despite leadership changes, the company maintains its strategy. Unlock your all-in-one trading dashboard ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

U.S.-listed shares of Novo Nordisk (NVO) are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook. The maker of blockbuster weight-loss ...